CN107224527A - Prevent and treat Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication and preparation method thereof - Google Patents
Prevent and treat Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication and preparation method thereof Download PDFInfo
- Publication number
- CN107224527A CN107224527A CN201710636828.XA CN201710636828A CN107224527A CN 107224527 A CN107224527 A CN 107224527A CN 201710636828 A CN201710636828 A CN 201710636828A CN 107224527 A CN107224527 A CN 107224527A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- percutaneous transluminal
- stent implantation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication and preparation method thereof, belong to technical field of traditional Chinese medicine preparation.A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, is made up of the raw material of following parts by weight：10 ~ 30 parts of Shuo Di, 10 ~ 30 parts of indigo naturalis, 5 ~ 20 parts of ovalleaf aspidistra rhizome, 5 ~ 20 parts of arrowhead, 3 ~ 15 parts of pine mushroom, 3 ~ 15 parts of leaf mustard, 3 ~ 15 parts of Chinese torreyanut, 1 ~ 10 part of common cattail, 1 ~ 10 part of Paphio-pedilum micranthum Tang et Wang.The present invention with it is promoting blood circulation and removing blood stasis, remove obstruction in channels to relieve pain as main principle of reatment, the effect of having supplementing qi and nourishing yin, heat-clearing and damp-drying drug concurrently is using Shuo Di and indigo naturalis as monarch drug in a prescription, using ovalleaf aspidistra rhizome and arrowhead as ministerial drug, it is all adjuvant with pine mushroom, leaf mustard, Chinese torreyanut, common cattail and Paphio-pedilum micranthum Tang et Wang, all medicine compatibilities, can effectively prevent and treat the occurrence and development of percutaneous transluminal coronary stent implantation infectious-related complication, eliminate susceptible factor.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine preparation, and in particular in a kind of preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication
Drug composition and preparation method thereof.
Background technology
Coronary heart disease is the most commonly seen ischemic cardiomyopathy of adult, at present, and the method for the treatment of coronary heart disease has 3 kinds, i.e., simple
Drug therapy, operation are put up a bridge, coronary angioplasty Stent.Wherein Percutaneous Intracoronary Arterial Stenting has turned into treatment warp
Skin coronary angioplasty (PTCA) afterwards coronary artery acute occlusion and reduce PTCA after ISR effective ways.Due to
Surgical injury is small, recovery is fast, good effect, and patient is easy to receive, but is found in clinic, and more patient is expert in coronary artery
Stenter to implant is preoperative and implantation during with anxiety, the mood of anxiety, Hypoaffectivity.
Coronary heart disease belongs to " obstruction of qi in the chest ", " angina pectoris " category of the traditional Chinese medical science, and the modern times think that its interpretation of the cause, onset and process of an illness always belongs to asthenia in origin and asthenia in superficiality, actually trembled with fear
The solidifying, stagnation of the circulation of vital energy, blood stasis, phlegm resistance, numbness resistance chest sun, stagnating heart meridian；Void is heart spleen caused by liver and kidney deficiency, and heart arteries and veins, which loses, supports, and actual situation is staggeredly through this
The whole process of disease.
Depression belongs to the traditional Chinese medical science " melancholia " category, and melancholia is caused by emotional discomfort, depression and stagnation of QI, to feel depressed, mood
The full vexed, distending pain in hypochondrium of not peaceful, chest, or irritability happiness are cried, or if any foreign matter the class that disease is main clinical manifestation such as block in pharynx
Disease.Its main pathogenesis is that liver dysfunction, the dysfunction of the spleen in transport, the heart are become homeless foster, internal organs yin and yang qi and blood disorder.Liver dysfunction, then mechanism of qi
Stasis；The dysfunction of the spleen in transport, the then turbid interior life of phlegm；The heart becomes homeless foster, then the biochemical weary source of qi and blood, agitates ineffective, QI-blood circulation is not smooth, with the passing of time cause
The stasis of blood.
The ratio of coronary stent implantation patient's combined postoperative depressive disorder is up to 39.1%.To find out its cause, patient suffers from coronary disease
The neurological susceptibility of the psychoreaction and presence of disease biologically to depressive disorder, results in the generation or recurrence of paralepsy.Research
It was found that, in the patient with the coronary artery disease newly diagnosed, during coronarography, 17% suffers from major depression disorder；
And depressive disorder increases the generation of cardiac event, a major depressive episode is that cardiac event occurs in postoperative 1 year of PCI is strong
Predictive factor；Nervous, depressive patient, which is often secreted, to be continued and excessive catecholamine, is easily inspired arrhythmia cordis, is triggered heart
Sudden death.
Clinically conventional medicament for treatment of depression is Deanxit (Flupentixol and Melitracen Tablets), and curative effect is determined, for
The remission effect of somatization symptom caused by mental handicape is more apparent, there is preferable synergy to mental depression, pair with it is depressed
Relevant symptom and sleep-disorder also have good efficacy, and itself and antianginal drug use in conjunction have to angina pectoris attacks
It is significant to improve.Therefore, clinically it is usually used in merging the patients with coronary artery disease of depressive state.But because the medicine is not suitable for being applied to the heart
Flesh infarct is recovered in early stage, various heart blocks, the patient such as heart failure, and has certain side effect and adverse reaction,
It is subject to certain restrictions its application in patients with coronary artery disease.
Chinese traditional treatment coronary heart disease PCI Postoperative Anxiety depression effects are notable.Tang can clearly etc.（Tang Keqing, Wang Gongli, Wang Haitao
The bright traditional Chinese medical science of clinical research [J] for treating coronary artery stent implantation retarded depression state Deng depression-resolvinggranule granules, 2012,27 (3):
624-626）Treat 36 PCI post-operative depression patients using strongly fragrant grain is self solved, total effective rate is 91.2%, can effectively reduction of patient it is tight
Open mood, curative effect affirmative.Magnificent tinkling of pieces of jade etc.（The magnificent tinkling of pieces of jade, Qiu Xin light Xin Ke Shu ' tablet for treating coronary heart disease improves to senile patients with coronary heart disease depressive emotion to be divided
Analyse [J] combination of Chinese tradiational and Western medicine cardiovascular and cerebrovascular diseases magazines, 2012,10 (11)：1289）Research shows that Xin Ke Shu ' tablet for treating coronary heart disease treats old coronary disease
Disease merges light modest depression mood curative effect preferably, efficient up to 92.1%.It is above-mentioned that there are some researches show rational anti depressant therapy
The Degree of Depression of patient can be mitigated, so as to improve the depressive symptom of patient；This has important face to the prognosis for improving patient
Bed meaning.But long-term practice is found, above-mentioned Chinese medicine preparation clinical treatment efficiency is generally relatively low, to patient mental's state and life
The raising degree of quality is very limited.
The content of the invention
In view of this, the technical problems to be solved by the invention are to provide a kind of Chinese medicine composition, and coronary artery bracket is implanted into
Postoperative melancholia is evident in efficacy, can be effectively improved the state of mind of patient.
To achieve the above object, the technical solution adopted in the present invention is：
A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, is made up of the raw material of following parts by weight：Shuo Di 10 ~
30 parts, 10 ~ 30 parts of indigo naturalis, 5 ~ 20 parts of ovalleaf aspidistra rhizome, 5 ~ 20 parts of arrowhead, 3 ~ 15 parts of pine mushroom, 3 ~ 15 parts of leaf mustard, 3 ~ 15 parts of Chinese torreyanut, Pu
1 ~ 10 part of dish, 1 ~ 10 part of Paphio-pedilum micranthum Tang et Wang.
Preferably, the Chinese medicine composition of the preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：15 ~ 25 parts of Shuo Di, 15 ~ 25 parts of indigo naturalis, 10 ~ 15 parts of ovalleaf aspidistra rhizome, 10 ~ 15 parts of arrowhead, 6 ~ 12 parts of pine mushroom, 6 ~ 12 parts of leaf mustard,
6 ~ 12 parts of Chinese torreyanut, 4 ~ 8 parts of common cattail, 4 ~ 8 parts of Paphio-pedilum micranthum Tang et Wang.
Preferably, the Chinese medicine composition of the preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：20 parts of Shuo Di, 20 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut, 6 parts of common cattail, flower
6 parts of leaf.
The preparation method of the Chinese medicine composition of above-mentioned preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, comprises the following steps：
Step S1：Dry Shuo Di and ovalleaf aspidistra rhizome are weighed respectively, is crushed, and mixing is added to supercritical CO2In extraction kettle, use
Ethanol is that entrainer is extracted, and obtains extract；
Step S2：Dry indigo naturalis, pine mushroom and Paphio-pedilum micranthum Tang et Wang are weighed, crushes, adds water, decocts, filters to obtain decoction liquor；
Step S3：The extract and decoction liquor are merged, concentrated, dries, obtains dry extract；
Step S4：The dry extract is merged with arrowhead, leaf mustard, Chinese torreyanut and the common cattail dried, ultramicro grinding obtains Ultramicro-powder.
Preferably, in step S1, the process conditions of the extraction are：10 ~ 15MPa of extracting pressure, extraction temperature 30 ~ 40
DEG C, CO235 ~ 45L/h of fluid flow, 1.5 ~ 2.0h of extraction time.
Preferably, in step S1, the volume fraction of the ethanol is 95%.
Preferably, in step S2, the weight ratio of the water and the raw material after crushing is 8 ~ 10：1.
Preferably, in step S2, the time of the decoction is 45 ~ 60 minutes.
Preferably, in step S3, the concentration is when being concentrated under reduced pressure into 75 DEG C after merging the extract and decoction liquor
Relative density is 1.20 ~ 1.25.
Compared with prior art, beneficial effects of the present invention are as follows：
1）It is of the present invention using Shuo Di and indigo naturalis as monarch drug in a prescription, using ovalleaf aspidistra rhizome and arrowhead as ministerial drug, with pine mushroom, leaf mustard, Chinese torreyanut, common cattail and flower
Leaf is all adjuvant, the collaboration of all medicines, and strongly fragrant, antitoxic heart-soothing and sedative, supplementing qi and nourishing yin, the clearing heat and detoxicating and work(removed obstruction in channels to relieve pain are dissipated with soothing the liver
Effect, can effectively prevent and treat the generation of melancholia after percutaneous transluminal coronary stent implantation, and notable to the therapeutic effect of postoperative melancholia.This
The pharmacology for inventing each raw medicinal material is as follows：
Shuo Di, are caprifoliaceae plant Shuo Di herb or root；Nature and flavor are sweet, acid, temperature；《Changsha medicine solution》：Enter the liver channel of foot-Jueyin.Function
Cure mainly dispelling wind and eliminating dampness, promoting blood circulation to remove blood stasis；
Indigo naturalis：For rank of nobility dinner party section plant acanthaceous indigo, polygonaceae plant indigo plant, legume wood blue, the leaf of cruciferae isatis or
Cauline leaf processed obtained dried powder or agglomerate, taste are salty；It is cold in nature, Return liver；Lung；Stomach, major function is clearing heat and detoxicating；Cool blood is stopped
Blood；Clearing liver-fire；
Ovalleaf aspidistra rhizome：For the rhizome of liliaceous plant ovalleaf aspidistra rhizome.Whole year can adopt.Nature and flavor toil, temperature.Major function promoting blood circulation to remove blood stasis, connects
Bone, analgesic is clearing heat and detoxicating；
Arrowhead：For the bulb of Notes On Alism At Aceae arrowhead.Nature and flavor are sweet；Slight bitter；Micro-pungent；Cold nature.Return liver；Lung；Spleen；Bladder warp.Work(
It can cure mainly：Promoting blood circulation and cooling blood；Cough-relieving is treating stranguria；Powder detoxifcation；
Pine mushroom, is the fructification of Tricholomataceae fungi Trichotoma matsutake.Nature and flavor are sweet, flat, nontoxic；Major function is stimulated the circulation of the blood and cause the muscles and joints to relax；Regulating qi-flowing for eliminating phlegm；
Dampness removing is not turbid.Main lumbocrural pain；It is numb in every limb；Grain does not relax；Abundant expectoration shortness of breath；Urine stranguria with turbid discharge；
Leaf mustard：For the young stem and leaf of crucifer mustard Lay.Alias mustard, big mustard, potherb mustard, wrinkle leaf mustard, yellow mustard, frost be not old, punching
Dish.It is warm-natured, it is pungent.People's lung, stomach, kidney channel.Major function facilitaing lung slit phlegm, middle benefit gas profit gas；
Chinese torreyanut：Also known as Chinese torreya, Chinese torreya, beautiful Chinese torreya, wild China fir, Bi.For the seed of taxaceae plant Chinese torreya.Nature and flavor：It is sweet；It is puckery；It is mild-natured.
Enter lung, stomach, large intestine channel.Desinsection；Disperse accumulations；Moisturize；
Common cattail：For one kind of the aquatic persistent root herbs of Typhaceae, the false stem of its leaf sheath obvolvent is edible.It is sweet cool in nature；Tool
There are clearing heat and cooling blood, inducing diuresis for removing edema.Motherland's medical science thinks, common cattail cures mainly under the five internal organs heart rotten smelly, oliguresis in perverse trend, mouth
Helvolus, acute mastitis, constipation, the disease such as burning pain in the epigastrium；
Paphio-pedilum micranthum Tang et Wang：For the herb of orchid Paphiopedilum micranthum.It is bitter in taste；It is cool.Channel tropism lung；The heart；Kidney channel.Major function heat-clearing is saturating
Rash；Clearing away the heart fire and tranquillizing.
2）More than side effect of the present invention based on existing western medical treatment and adverse reaction and Chinese traditional treatment curative effect is undesirable etc.
Known disadvantage proposes a kind of evident in efficacy, has active treatment effect to percutaneous transluminal coronary stent implantation infectious-related complication especially melancholia
Chinese medicine composition, and there is provided the Chinese medicine composition preparation method.Preparation method of the present invention using the raw material property of medicine and drug effect as
Basis, passes through process modification and parameter optimization so that each raw material can give full play to itself property of medicine, and enhancing medicine can be mutually cooperateed with again
Effect is acted on.Clinical practice proves, Chinese medicine composition of the present invention is to feeling depressed produced by patient after percutaneous transluminal coronary stent implantation, feelings
The clinical melancholia performance such as thread is not peaceful, the full vexed, distending pain in hypochondrium of chest, irritability happiness are cried, it is continuous using can substantially reduce even within more than 3 weeks
The generation of above-mentioned symptom is completely eliminated, also has good prevention for other common complications such as arrhythmia cordis, skin infection etc.
Effect.
Embodiment
For a better understanding of the present invention, present disclosure, but this hair are further fairly set out with reference to embodiment
Bright protection content is not limited solely to the following examples.In the following description, give a large amount of concrete details so as to
More thorough understanding of the invention is provided.It will be apparent, however, to one skilled in the art that the present invention can be with
It is carried out without one or more of these details.
Embodiment 1：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：20 parts of Shuo Di, 20 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut, 6 parts of common cattail, flower
6 parts of leaf.
The preparation method of the Chinese medicine composition of embodiment preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, including following step
Suddenly：
Step S1：Dry Shuo Di and ovalleaf aspidistra rhizome are weighed respectively, is crushed, and mixing is added to supercritical CO2In extraction kettle, use
Ethanol is that entrainer is extracted, and obtains extract；
Step S2：Dry indigo naturalis, pine mushroom and Paphio-pedilum micranthum Tang et Wang are weighed, crushes, adds water, decocts, filters to obtain decoction liquor；
Step S3：The extract and decoction liquor are merged, concentrated, dries, obtains dry extract；
Step S4：The dry extract is merged with arrowhead, leaf mustard, Chinese torreyanut and the common cattail dried, ultramicro grinding obtains Ultramicro-powder.
The process conditions of the extraction are：Extracting pressure 12MPa, 35 DEG C of extraction temperature, CO2Fluid flow 40L/h, extraction
Time 1.8h.
The volume fraction of the ethanol is 95%.
The concentration is that relative density is 1.23 when being concentrated under reduced pressure into 75 DEG C after merging the extract and decoction liquor.
Prepare gained Ultramicro-powder（Particle diameter≤75 μm）With single dose Vacuum Package, 10 grams every bag, superfine powder is used as.
Superfine powder application method is：Ultramicro-powder is washed open using warm water, each 5g, take after mixing it with water 150 ~ 200ml.
Embodiment 2：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：15 parts of Shuo Di, 15 parts of indigo naturalis, 10 parts of ovalleaf aspidistra rhizome, 10 parts of arrowhead, 6 parts of pine mushroom, leaf mustard 6,8 parts of Chinese torreyanut, 4 parts of common cattail, floral leaf
4 parts of son.
The preparation method of the Chinese medicine composition of embodiment preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, including following step
Suddenly：
Step S1：Dry Shuo Di and ovalleaf aspidistra rhizome are weighed respectively, is crushed, and mixing is added to supercritical CO2In extraction kettle, use
Ethanol is that entrainer is extracted, and obtains extract；
Step S2：Dry indigo naturalis, pine mushroom and Paphio-pedilum micranthum Tang et Wang are weighed, crushes, adds water, decocts, filters to obtain decoction liquor；
Step S3：The extract and decoction liquor are merged, concentrated, dries, obtains dry extract；
Step S4：The dry extract is merged with arrowhead, leaf mustard, Chinese torreyanut and the common cattail dried, ultramicro grinding obtains Ultramicro-powder.
The process conditions of the extraction are：Extracting pressure 10MPa, 30 DEG C of extraction temperature, CO2Fluid flow 35L/h, extraction
Time 1.5h.
Preferably, the volume fraction of the ethanol is 95%.
The concentration is that relative density is 1.21 when being concentrated under reduced pressure into 75 DEG C after merging the extract and decoction liquor.
Embodiment 3：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：25 parts of Shuo Di, 25 parts of indigo naturalis, 15 parts of ovalleaf aspidistra rhizome, 15 parts of arrowhead, 12 parts of pine mushroom, 12 parts of leaf mustard, 10 parts of Chinese torreyanut, common cattail 8
Part, 8 parts of Paphio-pedilum micranthum Tang et Wang.
The preparation method of the Chinese medicine composition of embodiment preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, including following step
Suddenly：
Step S1：Dry Shuo Di and ovalleaf aspidistra rhizome are weighed respectively, is crushed, and mixing is added to supercritical CO2In extraction kettle, use
Ethanol is that entrainer is extracted, and obtains extract；
Step S2：Dry indigo naturalis, pine mushroom and Paphio-pedilum micranthum Tang et Wang are weighed, crushes, adds water, decocts, filters to obtain decoction liquor；
Step S3：The extract and decoction liquor are merged, concentrated, dries, obtains dry extract；
Step S4：The dry extract is merged with arrowhead, leaf mustard, Chinese torreyanut and the common cattail dried, ultramicro grinding obtains Ultramicro-powder.
The process conditions of the extraction are：Extracting pressure 15MPa, 40 DEG C of extraction temperature, CO2Fluid flow 45L/h, extraction
Time 2.0h.
The volume fraction of the ethanol is 95%.
The concentration is that relative density is 1.25 when being concentrated under reduced pressure into 75 DEG C after merging the extract and decoction liquor.
Embodiment 4：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：18 parts of Shuo Di, 18 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 8 parts of pine mushroom, 8 parts of leaf mustard, 6 parts of Chinese torreyanut, 5 parts of common cattail, flower
5 parts of leaf.
The preparation method of the Chinese medicine composition of the present embodiment preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication refers to embodiment 1,
Repeat no more.
Embodiment 5：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：10 parts of Shuo Di, 12 parts of indigo naturalis, 5 parts of ovalleaf aspidistra rhizome, 6 parts of arrowhead, 3 parts of pine mushroom, 3 parts of leaf mustard, 5 parts of Chinese torreyanut, 1 part of common cattail, floral leaf
3 parts of son.
The preparation method of the Chinese medicine composition of the present embodiment preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication refers to embodiment 1,
Repeat no more.
Embodiment 6：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：12 parts of Shuo Di, 10 parts of indigo naturalis, 8 parts of ovalleaf aspidistra rhizome, 5 parts of arrowhead, 5 parts of pine mushroom, 5 parts of leaf mustard, 3 parts of Chinese torreyanut, 3 parts of common cattail, floral leaf
1 part of son.
The preparation method of the Chinese medicine composition of the present embodiment preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication refers to embodiment 1,
Repeat no more.
Embodiment 7：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：30 parts of Shuo Di, 30 parts of indigo naturalis, 18 parts of ovalleaf aspidistra rhizome, 20 parts of arrowhead, 15 parts of pine mushroom, 15 parts of leaf mustard, 14 parts of Chinese torreyanut, common cattail 10
Part, 10 parts of Paphio-pedilum micranthum Tang et Wang.
The preparation method of the Chinese medicine composition of the present embodiment preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication refers to embodiment 1,
Repeat no more.
Embodiment 8：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：28 parts of Shuo Di, 28 parts of indigo naturalis, 20 parts of ovalleaf aspidistra rhizome, 18 parts of arrowhead, 14 parts of pine mushroom, 14 parts of leaf mustard, loose 15 parts of Chinese torreyanut, common cattail 9
Part, 9 parts of Paphio-pedilum micranthum Tang et Wang.
Embodiment 9：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：20 parts of Shuo Di, 20 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut, 6 parts of common cattail, flower
6 parts of leaf, 6 parts of oyster, 6 parts of common evolvulus herb, 5 parts of bower actinidia root or leaf root, 5 parts of mouse hare dung.
The Chinese medicine composition of present invention preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication increases male on the basis of embodiment 1 ~ 8
The parts by weight of oyster 3 ~ 10, the parts by weight of common evolvulus herb 3 ~ 10, the parts by weight of bower actinidia root or leaf root 1 ~ 7, the parts by weight of mouse hare dung 1 ~ 7.Wherein, oyster：For
The long oyster of Ostreidae animal and the shell for belonging to animal together.It is salty, puckery, it is slightly cold.Enter liver, courage, kidney channel.It is transquilization with heavy material, it is calming the liver, receive
Hold back astringent or styptic treatment for spontaneous sweating, softening and resolving hard mass, relieving haperacidity analgesic.Common evolvulus herb：Convolvulaceae common evolvulus herb platymiscium common evolvulus herb, with all herbal medicine；Nature and flavor toil,
It is cool；Enter the warp of liver,spleen,kidney three；Major function heat-clearing, dampness removing.Bower actinidia root or leaf root：For the root of Actinidiaceae plant tara vine；Property
It is lightly seasoned；Micro-puckery；It is flat；Major function clearing heat and promoting diuresis；Wind expelling stagnation removing；Removing toxicity for detumescence；Hemostasis.Mouse hare dung：For pika Tibet
The excrement of pika；Whole year can adopt；The many heaps of excrement combine in hole；Receive after, well sifted soil picks sandstone, dried；It is bitter salty, temperature, nothing
Poison；《Traditional Chinese Medicine in Sichuan will》：" stimulate the menstrual flow, dissolving stasis.”
Decoction is made in above-mentioned four tastes Chinese medicine, coordinates superfine powder of the present invention to use.Specifically preparation method is：Weigh respectively oyster,
Common evolvulus herb, bower actinidia root or leaf root and mouse hare dung, are added water to cook 2 times, are decocted 45 minutes every time, and filtering merges each filtrate, filtrate is subtracted
Pressure is concentrated into paste, dry, pulverize, obtains fine powder, and the fine powder and peppermint oil are mixed into external preparation.
Gained external preparation coordinates above-mentioned Ultramicro-powder to be applied in combination, the effect that the our strengthening the spleen and replenishing qi of enhancing, strengthening the essence are calmed the nerves, and improves and suffers from
The improvement of person's spirit and psychological condition.The external preparation is uniformly applied to affected part before Ultramicro-powder is taken, and 2 ~ 3 are smeared daily
It is secondary, smeared according to acupuncture points such as state of an illness acupoint selection connected valleys, Danzhong, interior pass, Yanglingquan, Zusanli, chize, the sea of blood.
Embodiment 10：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the original of following parts by weight
Material is made：20 parts of Shuo Di, 20 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut, 6 parts of common cattail,
6 parts of Paphio-pedilum micranthum Tang et Wang, 3 parts of oyster, 3 parts of common evolvulus herb, 1 part of bower actinidia root or leaf root, 1 part of mouse hare dung.
Embodiment 11：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the original of following parts by weight
Material is made：20 parts of Shuo Di, 20 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut, 6 parts of common cattail,
6 parts of Paphio-pedilum micranthum Tang et Wang, 10 parts of oyster, 10 parts of common evolvulus herb, 7 parts of bower actinidia root or leaf root, 7 parts of mouse hare dung.
Comparative example 1：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：20 parts of Shuo Di, 20 parts of indigo naturalis, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut, 6 parts of common cattail, 6 parts of Paphio-pedilum micranthum Tang et Wang.
The comparative example omits the use of ovalleaf aspidistra rhizome and arrowhead, and preparation method refers to embodiment 1.
Comparative example 2：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：5 parts of Shuo Di, 5 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 6 parts of common cattail, 6 parts of Paphio-pedilum micranthum Tang et Wang.
The comparative example omits the use of pine mushroom, leaf mustard and Chinese torreyanut, and preparation method refers to embodiment 1.
Comparative example 3：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：5 parts of Shuo Di, 5 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut.
The comparative example omits the use of common cattail and Paphio-pedilum micranthum Tang et Wang, and preparation method refers to embodiment 1.
Comparative example 4：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, by the raw material of following parts by weight
It is made：5 parts of Shuo Di, 5 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut, 6 parts of common cattail, floral leaf
6 parts of son.
The comparative example reduces the usage amount of Shuo Di and indigo naturalis, and preparation method refers to embodiment 1.
Comparative example 5：A kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, formula is same as Example 1,
Except that：
The preparation method of the Chinese medicine composition is：
Dry Shuo Di, indigo naturalis, ovalleaf aspidistra rhizome, arrowhead, pine mushroom, leaf mustard, Chinese torreyanut, common cattail and Paphio-pedilum micranthum Tang et Wang are weighed, crushes, adds water, institute
The weight ratio of raw material after stating water and crushing is 9：1, decoct 50 minutes, filter to obtain decoction liquor, the decoction liquor is concentrated into 75
DEG C relative density is 1.23 lotion；The lotion is dried, ultramicro grinding obtains Ultramicro-powder.
Incompatibility is not present in 1 ~ comparative example of comparative example 5, meets the basic principle of Chinese prescription.
Observation of curative effect is with evaluating
1.1 choose patient after 240 percutaneous transluminal coronary stent implantations accepted for medical treatment in December, 2013 in June, 2017.By all patients with
Machine is divided into 8 groups, and every group of 30 patients are respectively：1 group is observed, 2 groups is observed, contrasts 1 group, contrast 2 groups, contrast 3 groups, contrast 4
Group, contrast 5 groups and control group.Through statistics, every group of patient in general information indexs such as age, sex composition ratio, the course of disease, illnesss
Upper no difference of science of statistics (P ＞ 0.05) is balanced comparable.
1.2 case inclusion criterias：All cases are to receive coronary artery bracket postoperative more than 2 weeks, acardia block, tight
Situations such as center of gravity force failure.
1.3 standards of grading：Using ZUNGShi SDSs (Serf-Rating Depression ScAlle,
SDS), 24 version Hamilton depressive scales (HAMD-24) carry out examination to the depression status of CSI postoperative patients.SDS amounts
The computational methods of table end product are as follows：First 20 topics are integrated and are added, total score is drawn, reconvert is into percentage index, index：
Total score (score)/total score full marks (80) × 100；Index is below 50%：Normal range (NR) (no depressive symptom)；Index 50% ~
59%：Minor depressive；Index 60% ~ 69%：Modest depression；Index is severe depression in 70% and the above.HAMD-24 scale score marks
Standard, total score<8 be that, without depression, 8 ~ 20 be minor depressive, and 21 ~ 35 be modest depression,>35 be severe depression.SDS and HAMD-24 are commented
Divide and reach that slight, moderate, the standard of severe depression can be defined as the depressive disorder of respective degrees.
The Degree of Depression of each group patient is not statistically significant (P ＞ 0.05), balanced comparable.
1.4 treatment method：All patients receive the routine medication of coronary heart disease, without treating in coronary heart disease during treatment
Medicine decoction.Observe 1 group of patient and give the superfine powder of embodiment 1, take after mixing it with water 150 ~ 200ml/ times, be administered orally, 2 times a day.Observation 2
Group patient gives 9 superfine powders of embodiment+external preparation, and superfine powder is taken after mixing it with water 150 ~ 200ml/ times, is administered orally, 2 times a day,
External preparation is applied at acupuncture point, 2 times a day.Contrast 1 group of patient and give the superfine powder of comparative example 1,150 ~ 200ml/ times, orally
Administration, 2 times a day.Contrast 2 groups of patients and give the superfine powder of comparative example 2,150 ~ 200ml/ times, be administered orally, 2 times a day.It is right
Than 3 groups patients give the superfine powder of comparative example 3,150 ~ 200ml/ times, are administered orally, 2 times a day.4 groups of patients of comparative example give
The superfine powder of comparative example 4,150 ~ 200ml/ times, is administered orally, 2 times a day.Comparative example 5 groups of patients give the Ultramicro-powder of comparative example 5
Agent, 150 ~ 200ml/ times, is administered orally, 2 times a day.Control group：Deanxit (Lundbeck pharmaceutical Co. Ltd of Denmark) is given,
0.125g, a point early, noon takes twice.It is within 1 week 1 course for the treatment of, treats 3 weeks.
1.5 observation index：All patients receive SDS and HAMD-24 evaluation and tests before treatment and after treatment, and observe before treatment
Rear blood routine, liver function, kidney work(and have no toxic side effect, adverse reaction.
1.6 efficacy evaluation：Standard course for the treatment of after terminating all patients receive again SDS and HAMD-24 evaluation and test, SDS indexes and
HAMD-24 fractions decline more than 40% person before relatively treating be effective；It is effective to decline 15% ~ 39% before relatively treating；Before relatively treating
Decline less than 14% or enhancer are invalid.
1.7 tcm clinical practice symptoms score：Eight groups of patients with after treatment 3 weeks, carry out symptom scores respectively before the treatment
（Refer to：Term And Long-term Clinical Effect [D] the Guangzhou traditional Chinese medicine of Wang Kan Chinese herb decoctions treatment Patients Undergoing Coronary Artery Bypass Grafting is big
Learn, 2006, the 25-26 pages）.Tcm clinical practice symptom is divided into primary symptom and time disease, is divided into 4 grades, asymptomatic meter 0 by its light and heavy degree
Point, wherein the cardinal symptom such as pectoralgia, uncomfortable in chest count 2 respectively, 4,6 points, shortness of breath, weak, palpitaition, cold limb, sweating, other diseases such as difference of receiving
Shape counts 1 respectively, 2,3 points.All symptom score sums are tcm clinical practice symptom score total score.
1.8 Investigation of life quality：Eight groups of patients before the treatment and treatment 3 weeks after, receive quality of life scale (SF- respectively
36) score.Compare before two groups of patients treatment and treatment 3 weeks after SF-36 score.
1.9 statistical procedures：All datas carry out statistical analysis using SPSS17.0 statistics softwares bag, count
Data is expressed as a percentage, χ2Inspection is analyzed；P ＜ 0.05 are that difference is statistically significant.
2.0 result of the test：
1）Depressive symptom Clinical efficacy comparison
1 eight groups of patient clinical Comparison of therapeutic of table [example/%]
,
Note：Obvious effective rate（%）=effective case/total case number of cases * 100%；It is efficient（%）=effectively case/total case number of cases * 100%；Always have
Efficiency（%）=obvious effective rate+effective percentage.
The result of table 1 shows, obvious effective rate：The obvious effective rate for observing 1 group is 93.3%, and the obvious effective rate of 2 groups of observation is 96.7%, contrast
The obvious effective rate that 5 groups of 1 group ~ contrast is below 60%, and the obvious effective rate of control group is only 33.3%.Compare obvious effective rate, observe 1 group and sight
Examine 2 groups has significant difference compared with control group, and 1 ~ 5 group of contrast is compared with control group without significant difference.Total effective rate：Observation 1
Group and the effective percentage of 2 groups of observation reach 100%, and contrast the effective percentage of 5 groups of 1 group ~ contrast below 85%, and control group has
Efficiency reaches 73.3%.Compare total effective rate, 2 groups of 1 group of observation and observation have significant difference compared with control group, contrast 1 ~ 5 group
Without significant difference compared with control group.
The above results show, Chinese medicine composition of the present invention has excellent therapeutic effect to CSI post-operative depressions, each raw material it
Between mutually coordinated realize above-mentioned curative effect.
2）Compare before treatment with SDS and HAMD-24 scorings after treatment
With Investigation of life quality result after treatment before 2 eight groups of patient's treatments of table
,
The result of table 2 shows, SDS indexes and HAMA diversity of values there are no significant (P before eight groups of patients' treatments>0.05).Treatment 3 weeks
Afterwards, 1）The SDS indexes after 1 group and 2 groups of treatments of observation are observed significantly lower than (P before treatment<0.05) it is, and bright compared with after control group treatment
Aobvious reduction (P<0.05)；Observe the obvious reduction of HAMA scorings after 1 group and 2 groups of treatments of observation, (P before substantially less than treating<
0.05), and less than (P after control group treatment<0.05).2）Observe the SDS indexes after 2 groups of treatments and HAMA scorings are superior to observation
1 group.3）Contrast the reduction of the SDS indexes after 1 group ~ contrast, 5 groups of treatments, (P before substantially less than treating<0.05), and compared with control group drop
It is low, but no significant difference；The scoring reductions of the HAMA after 1 group ~ contrast, 5 groups of treatments are contrasted, before treatment, and less than control
After group treatment, but there are no significant for difference.
3）Eight groups of patient clinical symptom score
Clinical symptoms score difference there are no significant (P before eight groups of patients treatment>0.05).Treat after 3 weeks, 1）Observe 1 group and sight
The score of the clinical symptoms after 2 groups of treatments is examined significantly lower than (P before treatment<0.05) (P is substantially reduced after treating, and compared with control group<
0.05).2）The score of the clinical symptoms after 2 groups of treatments is observed less than 1 group of observation.3）Contrast the clinic after 1 group ~ contrast, 5 groups of treatments
Symptom score is reduced, but no significant difference, and is less than after control group treatment, but no significant difference.Specifically it is shown in Table
3。
With clinical symptoms score statistical result after treatment before 3 eight groups of patient's treatments of table
,
4）Eight groups of life in patients investigation
SF-36 diversity of values there are no significant (P before eight groups of patients treatment>0.05).Treat after 3 weeks, 1）Observe 1 group and observation 2
SF-36 scorings after group treatment are significantly raised, are significantly higher than (P before treatment<0.05), and higher than (P after control group treatment<
0.05).2）Observe the scorings of the SF-36 after 2 groups of treatments and be superior to 1 group of observation.3）Contrast the SF-36 after 1 group ~ contrast, 5 groups of treatments
Scoring rise, before treatment, and is higher than after control group treatment, but there are no significant for difference.Specifically it is shown in Table 4.
With Investigation of life quality result after treatment before 4 eight groups of patient's treatments of table
,
Above-mentioned statistical result showed, Chinese medicine composition of the present invention has to treatment percutaneous transluminal coronary stent implantation infectious-related complication especially melancholia
There is significant curative effect.The present invention is not only evident in efficacy using Chinese medicine composition, and patient can be made to recover normal in shorter time
State, and human body vim and vigour can be adjusted on the whole, improve the human body state of mind, significantly reduce the ill symptomses such as depression, significantly
Improve life quality.
Finally illustrate, the above embodiments are merely illustrative of the technical solutions of the present invention and it is unrestricted, this area is common
Other modifications or equivalent substitution that technical staff is made to technical scheme, without departing from technical solution of the present invention
Spirit and scope, all should cover among scope of the presently claimed invention.
Claims (9)
1. a kind of Chinese medicine composition for preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication, it is characterised in that by the original of following parts by weight
Material is made：10 ~ 30 parts of Shuo Di, 10 ~ 30 parts of indigo naturalis, 5 ~ 20 parts of ovalleaf aspidistra rhizome, 5 ~ 20 parts of arrowhead, 3 ~ 15 parts of pine mushroom, 3 ~ 15 parts of leaf mustard,
3 ~ 15 parts of Chinese torreyanut, 1 ~ 10 part of common cattail, 1 ~ 10 part of Paphio-pedilum micranthum Tang et Wang.
2. the Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication is prevented and treated according to claim 1, it is characterised in that：Shuo Di
15 ~ 25 parts, 15 ~ 25 parts of indigo naturalis, 10 ~ 15 parts of ovalleaf aspidistra rhizome, 10 ~ 15 parts of arrowhead, 6 ~ 12 parts of pine mushroom, 6 ~ 12 parts of leaf mustard, Chinese torreyanut 6 ~ 12
Part, 4 ~ 8 parts of common cattail, 4 ~ 8 parts of Paphio-pedilum micranthum Tang et Wang.
3. the Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication is prevented and treated according to claim 1, it is characterised in that：Shuo Di
20 parts, 20 parts of indigo naturalis, 12 parts of ovalleaf aspidistra rhizome, 12 parts of arrowhead, 9 parts of pine mushroom, 9 parts of leaf mustard, 9 parts of Chinese torreyanut, 6 parts of common cattail, 6 parts of Paphio-pedilum micranthum Tang et Wang.
4. according to the preparation side of the Chinese medicine composition of any one of the claim 1 ~ 3 preventing and treating percutaneous transluminal coronary stent implantation infectious-related complication
Method, it is characterised in that comprise the following steps：
Step S1：Dry Shuo Di and ovalleaf aspidistra rhizome are weighed respectively, is crushed, and mixing is added to supercritical CO2In extraction kettle, second is used
Alcohol is that entrainer is extracted, and obtains extract；
Step S2：Dry indigo naturalis, pine mushroom and Paphio-pedilum micranthum Tang et Wang are weighed, crushes, adds water, decocts, filters to obtain decoction liquor；
Step S3：The extract and decoction liquor are merged, concentrated, dries, obtains dry extract；
Step S4：The dry extract is merged with arrowhead, leaf mustard, Chinese torreyanut and the common cattail dried, ultramicro grinding obtains Ultramicro-powder.
5. preventing and treating the preparation method of the Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication according to claim 4, it is special
Levy and be：In step S1, the process conditions of the extraction are：10 ~ 15MPa of extracting pressure, 30 ~ 40 DEG C of extraction temperature, CO2Fluid
35 ~ 45L/h of flow, 1.5 ~ 2.0h of extraction time.
6. preventing and treating the preparation method of the Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication according to claim 4, it is special
Levy and be：In step S1, the volume fraction of the ethanol is 95%.
7. preventing and treating the preparation method of the Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication according to claim 4, it is special
Levy and be：In step S2, the weight ratio of the water and the raw material after crushing is 8 ~ 10：1.
8. preventing and treating the preparation method of the Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication according to claim 4, it is special
Levy and be：In step S2, the time of the decoction is 45 ~ 60 minutes.
9. preventing and treating the preparation method of the Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication according to claim 4, it is special
Levy and be：In step S3, the concentration is relative density when being concentrated under reduced pressure into 75 DEG C after merging the extract and decoction liquor
For 1.20 ~ 1.25.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710636828.XA CN107224527A (en) | 2017-07-31 | 2017-07-31 | Prevent and treat Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710636828.XA CN107224527A (en) | 2017-07-31 | 2017-07-31 | Prevent and treat Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107224527A true CN107224527A (en) | 2017-10-03 |
Family
ID=59957805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710636828.XA Pending CN107224527A (en) | 2017-07-31 | 2017-07-31 | Prevent and treat Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107224527A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836354A (en) * | 2012-09-19 | 2012-12-26 | 史继红 | Medicament for treating depression |
-
2017
- 2017-07-31 CN CN201710636828.XA patent/CN107224527A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836354A (en) * | 2012-09-19 | 2012-12-26 | 史继红 | Medicament for treating depression |
Non-Patent Citations (4)
| Title |
|---|
| 唐可清等: "解郁颗粒治疗冠状动脉支架植入术后抑郁状态的临床研究", 《光明中医》 * |
| 张弘兴等: "丹蒌片改善冠脉支架植入术后抑郁障碍的临床研究", 《环球中医药》 * |
| 赵艳青等: "基于数据挖掘的现代中医药治疗抑郁症用药规律分析", 《中国中药杂志》 * |
| 金玉玲等: "心可舒片对老年冠心病患者抑郁情绪改善分析", 《中西医结合心脑血管病杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520694B (en) | Traditional Chinese medicine composition capable of treating chronic obstructive pulmonary disease in stabilization period and preparation method of composition | |
| CN103652360B (en) | Feed for curing pig paratyphus and preparation method thereof | |
| CN104351578A (en) | Compound feed for treating chicken internal lesion caused by overexertion and preparation method of compound feed for treating chicken internal lesion caused by overexertion | |
| CN104208418A (en) | Rosa laevigata michx health oral solution for securing essence, reducing urination and tonifying kidneys and preparation method thereof | |
| CN104013868B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof | |
| CN103520655B (en) | Traditional Chinese medicine composition for treating psoriasis vulgaris and preparation method thereof | |
| CN102872286B (en) | Traditional Chinese medicine composition for curing lumbar interveterbral disc protrusion and preparation method thereof | |
| CN104223297B (en) | A kind of schisandra chinensis health-care oral liquid of slow down aging and preparation method thereof | |
| CN103749824A (en) | Gynostemma pentaphyllum health-care tea capable of lowering blood sugar and blood pressure and preparation method thereof | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN105435197A (en) | Pharmaceutical composition for treating chronic lymphocytic thyroiditis and preparation method thereof | |
| CN104147460A (en) | Traditional Chinese medicinal preparation for treating Parkinson's disease and preparation method thereof | |
| CN102335370A (en) | Flavored medicinal composition for removing stasis and dredging collaterals, and preparation method thereof | |
| CN105435190A (en) | Traditional Chinese medicine composition for treating cold-heat jumble asthma and preparation method of traditional Chinese medicine composition | |
| CN107224527A (en) | Prevent and treat Chinese medicine composition of percutaneous transluminal coronary stent implantation infectious-related complication and preparation method thereof | |
| CN104689283A (en) | Medicine for treatment of spleen insufficiency damp-aggregating type chloasma and preparation method thereof | |
| CN104147575A (en) | Traditional Chinese medicine preparation for treating wind-cold lung-closure-type chronic bronchitis and preparation method thereof | |
| CN104258224A (en) | Schisandra chinensis oral solution for treating lung-and-kidney yin-deficiency type chronic bronchitis and preparation method thereof | |
| CN103520644B (en) | Traditional Chinese medicine composition used for treating phlegm stagnation type hyperlipidaemia and preparation method of composition | |
| CN107137689A (en) | A kind of Chinese medicine composition for treating menopausal syndrome | |
| CN106109916A (en) | A kind of Fructus Rosae Laevigatae health care oral liquid of slow down aging and preparation method thereof | |
| CN105998532A (en) | Preparation method for traditional Chinese medicine for treating Qi-stagnancy and blood stasis painful heel and composition of traditional Chinese medicine | |
| CN105031286A (en) | Chinese herb preparation for treating iron-deficiency anemia and preparation method thereof | |
| CN104857371A (en) | Medicine for treating colon cancer and preparation method thereof | |
| CN107485683A (en) | A kind of Chinese and Western medicine compound granule for preventing and treating after cardiac surgery complication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171003 |
|
| RJ01 | Rejection of invention patent application after publication |